Insmed Inc
INSMBuild a strategy around INSM
Insmed Inc AI Insights
Informational only. Not investment advice.Snapshot
- R&D spend of 695.9M TTM is 156% of revenue (447M) - pre-commercial biotech burning cash to advance pipeline[Research and Development TTM]
- FCF of -906M TTM with only 335M cash remaining; 1.2B investment purchases suggest recent capital raise deployed[Free Cash Flow TTM]
- P/S ratio of 93x vs industry median 4.1x - market pricing in massive revenue inflection from pipeline[Price to Sales Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 200M or new equity raise announced — Signals imminent dilution; current 335M insufficient for 12-month burn
- Total Revenue TTM: Quarterly revenue exceeds 150M (600M run rate) — Validates commercial traction needed to justify valuation
- Research and Development TTM: R&D/Revenue ratio drops below 100% — Indicates transition from development to commercialization phase
Bull Case
Gross margin of 77% TTM demonstrates strong unit economics; if pipeline succeeds, operating leverage is massive with 1.3B opex base already built
Working capital of 1.5B provides 18+ months runway even at current burn; recent 1.2B investment activity suggests strategic deployment
Bear Case
Burning 906M FCF annually with 335M cash - dilutive financing imminent; stock issuance history (-256K) shows willingness to dilute
93x P/S requires flawless execution; any pipeline setback destroys thesis given zero margin of safety at current valuation
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage INSM's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway is critical constraint - current burn rate exhausts reserves within 6 months without financing
- FCF burn of -906M TTM vs 335M cash
- R&D intensity at 156% of revenue
- Debt/equity 0.61 limits debt capacity
Revenue must inflect 5-10x to justify 42B market cap given current 447M TTM revenue base
- EV/Revenue of 94x requires blockbuster
- Gross margin 77% supports scale leverage
- Operating loss 990M needs revenue offset
Valuation Context
Caveats
Public Strategies Rankings
See how Insmed Inc ranks across different investment strategies.
Leverage INSM's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
INSM Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$30.89B | — | ||
$30.97B | — | ||
0.00 | — | ||
$606.42M | +66.7% | — | |
$-6.42 | — | ||
-164% | +52.2% | — | |
-211% | +40.7% | — | |
$-967.58M | — | ||
-249% | — | ||
Beta 5Y (Monthly) | unknown | — |
INSM Dividend History
INSM Stock Splits
INSM SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
02/19/26 | 12/31/25 | Unknown | |
10/30/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
02/20/25 | 12/31/24 | Unknown | |
10/31/24 | 09/30/24 | 10-Q | |
08/08/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
02/22/24 | 12/31/23 | 10-K | |
10/26/23 | 09/30/23 | 10-Q | |
08/03/23 | 06/30/23 | 10-Q | |
05/04/23 | 03/31/23 | 10-Q | |
02/23/23 | 12/31/22 | 10-K | |
10/27/22 | 09/30/22 | 10-Q | |
08/04/22 | 06/30/22 | 10-Q | |
05/05/22 | 03/31/22 | 10-Q | |
02/17/22 | 12/31/21 | 10-K | |
10/28/21 | 09/30/21 | 10-Q | |
08/05/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
02/25/21 | 12/31/20 | 10-K | |
10/29/20 | 09/30/20 | 10-Q | |
08/06/20 | 06/30/20 | 10-Q | |
04/30/20 | 03/31/20 | 10-Q | |
02/25/20 | 12/31/19 | 10-K | |
10/30/19 | 09/30/19 | 10-Q | |
08/01/19 | 06/30/19 | 10-Q | |
05/07/19 | 03/31/19 | 10-Q | |
02/22/19 | 12/31/18 | 10-K | |
10/30/18 | 09/30/18 | 10-Q | |
08/02/18 | 06/30/18 | 10-Q | |
05/02/18 | 03/31/18 | 10-Q | |
02/23/18 | 12/31/17 | 10-K | |
11/02/17 | 09/30/17 | 10-Q | |
08/03/17 | 06/30/17 | 10-Q | |
05/03/17 | 03/31/17 | 10-Q | |
02/23/17 | 12/31/16 | 10-K | |
11/03/16 | 09/30/16 | 10-Q | |
08/04/16 | 06/30/16 | 10-Q | |
05/05/16 | 03/31/16 | 10-Q | |
02/25/16 | 12/31/15 | 10-K | |
11/06/15 | 09/30/15 | 10-Q | |
08/06/15 | 06/30/15 | 10-Q | |
05/07/15 | 03/31/15 | 10-Q | |
02/27/15 | 12/31/14 | 10-K | |
11/06/14 | 09/30/14 | 10-Q | |
08/06/14 | 06/30/14 | 10-Q | |
05/08/14 | 03/31/14 | 10-Q | |
03/06/14 | 12/31/13 | 10-K | |
11/05/13 | 09/30/13 | 10-Q | |
08/06/13 | 06/30/13 | 10-Q | |
05/07/13 | 03/31/13 | 10-Q | |
03/18/13 | 12/31/12 | 10-K | |
11/07/12 | 09/30/12 | 10-Q | |
08/07/12 | 06/30/12 | 10-Q | |
05/08/12 | 03/31/12 | 10-Q | |
03/13/12 | 12/31/11 | 10-K | |
11/09/11 | 09/30/11 | 10-Q | |
08/08/11 | 06/30/11 | 10-Q | |
05/10/11 | 03/31/11 | 10-Q | |
03/16/11 | 12/31/10 | 10-K | |
11/09/11 | 09/30/10 | 10-Q | |
08/04/10 | 06/30/10 | 10-Q | |
05/06/10 | 03/31/10 | 10-Q | |
03/16/10 | 12/31/09 | 10-K | |
11/09/09 | 09/30/09 | 10-Q | |
11/03/10 | 09/30/09 | 10-Q | |
08/13/09 | 06/30/09 | 10-Q | |
05/13/09 | 03/30/09 | 10-Q | |
03/31/09 | 12/31/08 | 10-K | |
11/05/08 | 09/30/08 | 10-Q | |
08/08/08 | 06/30/08 | 10-Q | |
05/09/08 | 03/30/08 | Unknown | -- |
03/12/08 | 12/31/07 | 10-K | |
11/09/07 | 09/30/07 | 10-Q | |
08/06/07 | 06/30/07 | 10-Q | |
05/10/07 | 03/30/07 | Unknown | -- |
03/16/07 | 12/31/06 | 5 | |
11/08/06 | 09/30/06 | 10-Q | |
08/09/06 | 06/30/06 | 10-Q | |
05/09/06 | 03/30/06 | Unknown | -- |
03/06/06 | 12/31/05 | 5 | |
11/07/05 | 09/30/05 | 10-Q | |
08/09/05 | 06/30/05 | 10-Q | |
05/10/05 | 03/30/05 | Unknown | -- |
03/16/05 | 12/31/04 | 5 | |
11/09/04 | 09/30/04 | 10-Q | |
08/09/04 | 06/30/04 | 10-Q | |
05/10/04 | 03/30/04 | Unknown | -- |
03/12/04 | 12/31/03 | 4 | |
11/14/03 | 09/30/03 | 10-Q | |
08/12/03 | 06/30/03 | 10-Q | |
05/15/03 | 03/30/03 | Unknown | -- |
03/28/03 | 12/31/02 | 10-K | |
11/08/02 | 09/30/02 | 10-Q | |
08/09/02 | 06/30/02 | 10-Q | |
05/14/02 | 03/30/02 | Unknown | -- |
03/25/02 | 12/31/01 | 10-K405 | |
11/08/01 | 09/30/01 | 10-Q | |
08/08/01 | 06/30/01 | 10-Q | |
05/03/01 | 03/30/01 | Unknown | -- |
03/22/01 | 12/31/00 | 10-K | |
11/14/00 | 09/30/00 | 10-Q | |
08/14/00 | 06/30/00 | 10-Q | |
07/17/00 | 03/30/00 | Unknown | -- |